156 related articles for article (PubMed ID: 3902267)
21. [Combination chemo-endocrine therapy of metastatic and stage IV breast cancer with cyclophosphamide, adriamycin, prednisolone and tamoxifen (CAPT)--with special reference to management of brain and liver metastasis].
Nakamura Y; Kawaguchi M; Hata A; Watanabe H; Ueki Y; Oribe T; Koba F; Takamuku K
Gan To Kagaku Ryoho; 1989 Feb; 16(2):243-50. PubMed ID: 2919892
[TBL] [Abstract][Full Text] [Related]
22. Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer.
De Lena M; Brambilla C; Morabito A; Bonadonna G
Cancer; 1975 Apr; 35(4):1108-15. PubMed ID: 1116104
[TBL] [Abstract][Full Text] [Related]
23. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
24. Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer.
Steiner R; Stewart JF; Cantwell BM; Minton MJ; Knight RK; Rubens RD
Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1553-7. PubMed ID: 6357805
[TBL] [Abstract][Full Text] [Related]
25. A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer.
Smalley RV; Lefante J; Bartolucci A; Carpenter J; Vogel C; Krauss S
Breast Cancer Res Treat; 1983; 3(2):209-20. PubMed ID: 6688538
[TBL] [Abstract][Full Text] [Related]
26. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.
J Clin Oncol; 1988 Apr; 6(4):679-88. PubMed ID: 2895801
[TBL] [Abstract][Full Text] [Related]
27. A randomized, prospective, comparative, multicentre trial of a single combination versus alternating combinations of antitumour drugs in advanced breast cancer.
Spittle MF; Hill BT; Ostrowski MJ; Macrae KD; Bates TD; Martin WM; Nicol NT; Edelstyn GA
Eur J Cancer Clin Oncol; 1987 Aug; 23(8):1155-62. PubMed ID: 3308483
[TBL] [Abstract][Full Text] [Related]
28. Clinical controlled trial in advanced breast cancer: CMFV (cyclophosphamide, methotrexate, fluorouracil, vincristine) verus CD (carminomycin, dibromodulcitol).
Neoplasma; 1982; 29(6):741-7. PubMed ID: 6761595
[TBL] [Abstract][Full Text] [Related]
29. [Treatment of metastasized breast cancer].
Thurm K
Z Erkr Atmungsorgane; 1986; 166(1):112-5. PubMed ID: 3953107
[TBL] [Abstract][Full Text] [Related]
30. Alternating versus sequential therapy in advanced breast cancer.
Romero A; Rabinovich MG; Pérez JE; Macchiavelli M; Leone BA; Strauss E; Goldar D; Alvarez LA; Vallejo C
Medicina (B Aires); 1987; 47(3):243-8. PubMed ID: 3326994
[No Abstract] [Full Text] [Related]
31. Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study.
Calabresi F; Di Lauro L; Marolla P; Curcio CG; Paoletti G; Calabró A; Giannarelli D; Ballatore P; Foggi CM; Di Palma M
Semin Oncol; 1991 Apr; 18(2 Suppl 4):66-72. PubMed ID: 2031201
[TBL] [Abstract][Full Text] [Related]
32. [Chemotherapy using the CMF regimen (cyclophosphamide, methotrexate, and 5-fluorouracil) and the VAC protocol (vincristine, adriamycin and cyclophosphamide) in patients with advanced breast cancer].
Glińska H; Zulichowska J; Radziszewska J; Sukiennik-Siuda M; Trabka E
Nowotwory; 1987; 37(3):251-61. PubMed ID: 3438177
[No Abstract] [Full Text] [Related]
33. Low-dose mitomycin and weekly low-dose doxorubicin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, and 5-fluorouracil.
Colozza M; Tonato M; Grignani F; Davis S
Cancer; 1988 Jul; 62(2):262-5. PubMed ID: 3383126
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients. A randomized trial.
Viladiu P; Alonso MC; Avella A; Beltrán M; Borrás J; Ojeda B; Bosch FX
Cancer; 1985 Dec; 56(12):2745-50. PubMed ID: 3902200
[TBL] [Abstract][Full Text] [Related]
35. Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. Danish Breast Cancer Cooperative Group (DBCG).
Andersson M; Madsen EL; Overgaard M; Rose C; Dombernowsky P; Mouridsen HT
Eur J Cancer; 1999 Jan; 35(1):39-46. PubMed ID: 10211086
[TBL] [Abstract][Full Text] [Related]
36. [Combination chemotherapy with methotrexate, vincristine, cis-platinum, cyclophosphamide, adriamycin, and bleomycin: MVP-CAB for disseminated urological cancer].
Fujii A; Morishita S; Nakamura I; Oka Y; Ohshima H; Nagata H; Iwamoto T; Itoh N; Nakagawa Y; Miyazaki S
Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):55-62. PubMed ID: 1691254
[TBL] [Abstract][Full Text] [Related]
37. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
[TBL] [Abstract][Full Text] [Related]
38. [Adriamycin, cyclophosphamide, vincristine and methotrexate combination chemotherapy of small cell lung cancer].
Saito H; Kawatsu H; Saka H; Yamamoto M; Takagi E; Tsunekawa H; Kawachi H; Nagura E; Sakai S; Nishiwaki K
Gan To Kagaku Ryoho; 1988 Jun; 15(6):1909-13. PubMed ID: 2838000
[TBL] [Abstract][Full Text] [Related]
39. VP-16 and adriamycin in patients with advanced breast cancer.
Vaughn CB; Maniscalco-Greb E; Lockhard C; Groshko G; Enochs K; Duffin H; Demitrish M
Am J Clin Oncol; 1982 Oct; 5(5):505-9. PubMed ID: 6897491
[TBL] [Abstract][Full Text] [Related]
40. Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.
Mikhak B; Zahurak M; Abeloff MD; Fetting JH; Davidson NE; Donehower RC; Waterfield W; Kennedy MJ
Cancer; 1999 Feb; 85(4):899-904. PubMed ID: 10091768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
